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Abstract  
BACKGROUND: Red blood cell (RBC) alloimmunization is still an actual problem in our transfusion practice. In 
2011, in addition to the regular ABO/D blood group typing, phenotyping for Rh (C, c, E, e) and Kell antigens was 
introduced for blood donors and patients undergoing blood transfusion. Our aim was to evaluate the impact of the 
extended RBC typing and donor/recipient matching on the incidence of RBC alloimmunization. 
METHODS: A retrospective comparative study was conducted by reviewing RBC request records for about 
36,000 patients transfused with RBC in the period from 2013 to 2015 in comparison to the similar study conducted 
on 47,000 transfused patients in the period from 2005 to 2008. Pre-transfusion serologic testing data were 
retrieved for analysis. Blood samples with positive antibody screening and positive cross-match were further 
subjected to antibody identification. All the tests were performed using column agglutination technique (CAT) with 
ID-cards and reagents from DiaMed in both studies.
 
RESULTS: Irregular RBC alloantibodies were detected in 116 (0.32%) out of 36,000 transfused patients. Multiple 
transfusions (15.8 units/patient) were given to 450 patients from which 79 (17.5%) had RBC allontibodies. The 
incidence of RBC alloimmunisation in the rest of the 35,550 transfused patients from which 37 had RBC 
alloantibodies was 0.10%. A total of 117 alloantibodies were identified in 96 out of the 116 patients with irregular 
RBC antibodies. Their specificity was as fallows: anti-E (25.6%), -C (6.0%), -c (8.5%), -e (0.85%), -C
w
 (5.1%), -K 
(12.8%), -Fy
a
 (10.2%), -Fy
b
 ( 2.5%), -Jk
a
 (7.7%), -Jk
b
 (2.5%), -M (9.4%), -S (1.7%), -s (0.85%), -Lu
a
 (1.7%), -Le
b
 
(3.4%) and anti-Le
b 
(0.85%). Multiple antibodies were identified in 22 of the transfused patients out of which 15 
(68.2%) received multiple transfusions. Anti-E was the most common antibody found in more of the 50% of the 
multiple antibody cases.  
CONCLUSIONS: The overall incidence of RBC alloimmunization in transfused patients decreased from 0.51% 
which was the estimated incidence for the period before the introduction of the extended RBC typing (2005-2008) 
to 0.32% (2013-2015). This is due to the decreased incidence of RBC alloimmunization in the multiply transfused 
patients from 33.9% to 17.5% respectively. The current frequency of anti-E (25.6%) and -K (12.8%) antibodies in 
transfused patients are significantly lower than their previous estimated frequencies of 30.4% and 24.0% 
respectively, as well as the overall frequency of RBC antibodies to Rh+Kell antigens which decreased from 72.4% 
to 53.8%. Extended donor-recipient matching for C, c, E, e and Kell antigens has proved a beneficial effect on the 
incidence of RBC alloimmunization in multiply transfused patients. 
 
 
 
 
 
 
Introduction 
 
Red blood cell alloimmunization results from 
the genetic red blood cell antigen disparity between 
donor and recipient or from mother and fetus. The 
surface of the red blood cell (RBC) is coated with 
antigens (sugars and proteins) that are integrally 
linked to membrane proteins or lipids. The clinical 
relevance of these antigens for blood component 
transfusion and tissue/organ transplantation lies in the 
ability of these surface molecules to initiate an 
immune response [1].  
The way the immune system reacts depends 
on several factors. The immune response to 
carbohydrate antigens is usually thymus independent. 
Multivalent antigens directly stimulate B cells to 
synthesise antibodies without the aid of helper T cells 
resulting in the majority of cases in the production of 
IgM antibodies. Individuals lacking a particular 
carbohydrate blood group antigen on their red cells 
can have ‘naturally occurring' IgM antibodies, which 
are most probably stimulated by cross-reacting 
antigens present in the environment, such as on gut 
bacteria. The most important carbohydrate antigens 
for blood transfusion practice are the A- and B-
antigens. Normal individuals who lack either the A or 
Basic Science 
_______________________________________________________________________________________________________________________________ 
_______________________________________________________________________________________________________________________________ 
  108                                                                                                                                                                                                                     http://www.mjms.mk/ 
http://www.id-press.eu/mjms/ 
 
B antigen make IgM B or A antibodies, respectively. 
Since IgM antibodies are complement-binding, these 
antibodies can cause immediate and severe 
intravascular hemolysis after transfusion of 
incompatible red cells, which can lead to serious or 
fatal complications [2].  
The discovery of the AB0 blood group system, 
by the Austrian pathologist Karl Landsteiner [3] and 
the introduction of the AB0 blood grouping test for 
selected donors by Ottenberg [4] in 1911 greatly 
reduced the fatalities associated with blood 
transfusion in the early days of transfusion therapy. 
Despite the ABO matching, hemolytic transfusion 
reactions were reported in 1921 by Unger [5], and 
additional tests were recommended to exclude the 
possibility of a recipient's serum agglutinating the 
donor's red cells due to the presence of non-ABO 
antibodies, now known as irregular alloantibodies. 
These alloantibodies are directed against the 
numerous other blood group antigens which reside on 
membrane proteins and comprise polymorphic 
determinants dependent primarily on amino acid 
sequence. These protein antigens can stimulate a 
thymus-dependent immune response, and the 
resulting IgG antibodies can cause extravascular 
clearance of antigen-positive cells. These IgG 
antibodies may also cross the placenta, resulting in 
hemolytic disease of the newborn. 
 
Currently, 35 blood group systems and 342 
antigens are recognised by the Working Party 
committee on terminology for red cell surface antigens 
of the International Society of Blood Transfusion 
(ISBT). The most important irregular red blood cell 
alloantibodies in daily transfusion practice, in terms of 
clinical significance and frequency of occurrence, are 
directed towards the RH (anti-D, -C, -E, -c and -e), 
KEL (anti-K), FY (anti-Fya and -Fyb ), JK (anti-Jka 
and -Jkb ) and the MNS (anti-M, -S and -s) blood 
group systems [6]. Of these, the D-antigen is the most 
immunogenic, resulting in more than 80% of 
immunocompetent D negative persons becoming allo 
immunised after a transfusion of D-positive 
erythrocytes [7]. This has resulted in the prophylactic 
matching of red cell transfusions for the D-status. 
Such routine is not sufficient to prevent other RBC 
antibodies, for which we rely on serologic screening 
before transfusion. 
 
Retrospective studies in the general 
population reported antibody frequencies after 
transfusion of less than 1 to 3 percent. However, in 
multi-transfused patients alloimmunization occurs 
from 10-38% and up to 60-70% of patients [8-11]. 
Whether the recipient's immune system will 
produce RBC antibodies depends on genetic and 
acquired patient-related factors, antigen frequency in 
the population, dose and number of expositions 
(transfusions) and the immunogenicity of the RBC 
antigen as it is shown in Table 1 [12]. 
Table 1: Frequent clinically significant RBC antibodies 
Antigen System Antibody 
frequency 
 
Antigen 
frequency 
(Whites) 
Antigen 
frequency 
(Blacks) 
Potential* 
E Rh 16-40% 30% 2% 4% 
Kell (Kl) Kell 5-40% 9% 3% 9% 
D Rh 8-33% 85% 92% 70% 
C Rh 4-15% 80% 99% 4% 
Jk(a) Kidd 2-13% 77% 91% 0.14% 
Fy(a) Duffy 4-12% 63% 10% 0.46% 
c Rh 2-10% 70% 32% 0.22% 
e Rh 2-3% 98% 98% 1% 
Jk(b) Kidd 2% 72% 43% 0.06% 
S MNSs 1-2% 55% 31% 0.08% 
s MNSs <1% 89% 97% 0.06% 
* Percentage of antigen-negative recipients who become allo immunized if transfused with 
antigen-positive units. 
 
Clinical manifestations of RBC antibodies are 
acute intravascular hemolytic transfusion reactions 
(rarely a consequence of alloimmunization and almost 
always caused by ABO antibodies), delayed hemolytic 
transfusion reactions (DHTRs) (hemolysis caused by 
RBC alloantibodies at least 24 hours posttransfusion) 
and hemolytic disease in newborns (mother's 
alloimmunization against fetal antigens, most often 
resulting from previous pregnancies). 
Nowadays, after 70 years of transfusion 
practice, RBC alloimmunization is still an actual 
problem in our pre-transfusion testing. It is a cause for 
a delay in transfusion treatment of the alloimmunized 
patients because antigen-negative RBC must be 
provided which can be difficult in a patient with rare 
and multiple alloantibodies.
 
In 2011, in addition to the regular ABO/D 
blood group typing, routine phenotyping for Rh (C, c, 
E, e) and Kell antigens was introduced in blood 
donors and patients undergoing a blood transfusion. 
Our aim was to evaluate the impact of the extended 
RBC typing and donor/recipient matching on the 
incidence of RBC alloimmunization.
 
 
 
Methods  
 
A retrospective comparative study was 
conducted by reviewing RBC request records for 
about 36,000 patients transfused with RBC in the 
period from 2013 to 2015 in comparison to the similar 
study conducted on 47,000 transfused patients in the 
period from 2005 to 2008. Pre-transfusion serologic 
testing data were retrieved for analysis.  
Blood samples with positive antibody 
screening or/and positive cross-match were further 
subjected to antibody identification. All the tests were 
performed using column agglutination technique 
(CAT) with ID-cards and reagents from DiaMed in 
both studies.
 
We compared the sex, number of transfusions 
and specificity of the revealed alloantibodies as well 
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as the overall incidence of alloimmunization in the two 
groups of transfused patients in the above mentioned 
periods, i.e., the period before and after the 
introduction of routine extended Rh (C, c, E, e) and 
Kell antigen typing. 
 
 
Results 
 
In the period from 2005 to 2008 irregular red 
cell antibodies were detected in 53 (0.11%) out of 
46,459 transfused patients and in 188 (33.9%) out of 
554 multiply transfused patients. The overall incidence 
rate of immunisation due to RBC transfusion in the 
total of 47,013 transfused patients was 0.51%, and 
the total number of patients with positive antibody 
screening was 241 (Table 2).
 
In the period from 2013 to 2015 irregular red 
cell antibodies were detected in 37 (0.10%) out of 
35,550 transfused patients and in 79 (17.5%) out of 
450 multiply transfused patients. The overall incidence 
rate of immunisation due to RBC transfusion in the 
total of 36,000 transfused patients was 0.32%, and 
the total number of patients with positive antibody 
screening was 116 (Table 2).
 
The incidence of alloimmunization in the 
multiply transfused patients decreased from 33.9% to 
17.5% which lead to the decrease of the overall 
incidence of RBC alloimmunization in transfused 
patients from 0.51% to 0.32% respectively. However, 
irregular RBC antibodies were significantly more 
frequent in the multiply transfused patients in 
comparison to transfused patients in both periods (p < 
0.05).  
Table 2: Immunisation to red blood cell antigens in transfused 
patients 
 
Transfused patients 
No 
Immunization patients
 
No (%) 
Transfusions 
Average No 
(2005-08) (2013-15) (2005-08) (2013-15) (2005-08) (2013-15) 
554 450 188 (33.9) 79 (17.5) 16.7 15.8 
46459 35550 53 (0.11) 37 (0.10) 1.74 1.72 
47013 36000 241 (0.51) 116 (0.32)  
 
According to the sex, there was no difference 
between the number of male and female transfused 
patients in the two observed periods, i.e. the period 
before (2005-2008) and the period after the 
introduction of extended RBC typing (2013-2015). 
Significant difference in the occurrence of 
immunization between male 60 (32.4%) and female 
128 (67.7%) multiply transfused patients was 
observed in the period from 2005 to 2008, as it was in 
the period from 2013 to 2015 being 31 (39.3%) male 
and 48 (60.7%) female patients (p<0.05).  
There was no significant difference between 
the two groups of multiply transfused patients 
according to the number of transfusions (Table 2).  
Also, there was no significant difference in the 
rate of alloimmunization between the two groups of 
multiply transfused patients according to the diagnosis 
as shown in Table 3. 
 
Table 3: Rate of RBC alloimmunization according to the 
diagnosis 
Diagnosis Patients 
No 
Alloimmunization 
No (%) 
(2005-2008) (2013-2015) (2005-2008) (2013-2015) 
Leucosis in adults 217 125 107 (56.9) 43 (54.4) 
Leucosis in children 78 82 16 (8.5) 7 (8.8) 
Chronic renal failure 109 116 29 (15.4) 16 (20.2) 
Internal patients 83 94 23 (12.2) 9 (12.6) 
Surgical patients 67 33 13 (6.9) 4 (5.0) 
Total 554 450 188 (33.9) 79 (17.5%) 
 
In 126 (52.3%) out of 241 transfused patients 
with irregular antibodies, 138 clinically significant 
antibodies were identified in the period from 2005-to 
2008 in comparison to 117 alloantibodies which were 
identified in 96 (82%) out of the 116 transfused 
patients in the period from 2013 to 2015. Specificity of 
the identified antibodies is shown in Table 4.
 
Table 4: Antibody specificity in transfused patients 
   Period 
Antibody 2005-2008 
No (%) 
2013-2015 
No (%) 
E 42 (30.4) 30 (25.6) 
C 15 (10.8) 7 (6.0) 
c 8 (5.8) 10 (8.5) 
e 2 (1.4) 1 (0.85) 
C
w
 4 (2.9) 6 (5.1) 
K 33 (24.0) 15 (12.8) 
Fy
a
 6 (4.3) 12 (10.2) 
Fy
b
 1 (0.7) 3 (2.5) 
Jk
a
 8 (5.8) 9 (7.7) 
Jk
b
 2 (1.4) 3 (2.5) 
M 5 (3.6) 11 (9.4) 
S / 2 (1.75) 
s 1 (0.72) 1 (0.85) 
Lu
a
 2 (1.4) 2 (1.7) 
Le
b
 3 (2.2) 4 (3.4) 
Le
a
 4 (2.9) 1 (0.85) 
Total 138 117 
 
Multiple antibodies were identified in 9 (7.1%) 
out of 126 patients with specific alloantibodies from 
which 7 (77.7 %) were multiply transfused in the 
period from 2005 to 2008. In comparison to that, 22 
(18.9%) out of 96 patients had multiple antibodies 
from which 15 (68.2%) received multiple transfusions. 
The current occurrence of multiple alloantibodies 
(68.2%) was lower in a patient with multiple 
transfusions in comparison to the period before 
extended RBC typing was introduced. Anti-E was the 
most common antibody found in more of the 50% of 
the multiple antibody cases.  
The risk of alloimmunization to anti-E and 
anti-K is 297.47 times greater (RR=68.21 r<0.05) in 
multiply transfused patients in comparison to 
transfused patients. The frequency of RBC antibodies 
to Rh+Kell antigens decreased from 100 (72.4%) to 
63 (53.8%) identified alloantibodies which are mostly 
due to the decreased frequency of E and K 
antibodies.
 
The current frequency of E which is 30 
(25.6%) antibodies and for K which is 15 (12.8%) 
antibodies in transfused patients is significantly lower 
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(
2 
= 12.7, p < 0.01) than their previous (2005-2008) 
estimated frequencies of 42 (30.4%) antibodies and 
33 (24.0%) antibodies respectively.  
 
 
Discussion 
 
Despite the relatively high frequency of RBC 
alloimmunization, clinical manifestations of hemolytic 
transfusion reactions are rare (approximately 0.05% of 
patients transfused) due to the regular ABO/D 
matching and serologic patient/donor cross-matching 
[12]. Acute hemolytic transfusion reactions due to 
ABO mismatched RBC transfusions almost always 
occur as a clerical error (misidentification of the 
patient/blood sample or incorrect blood component 
transfused) [13]. 
Delayed hemolytic transfusion reactions 
(DHTRs) can occur if the alloantibody titer drops 
below detectable levels (which is nowadays rarely the 
case with the column agglutination technique used for 
the compatibility testing), or in very rare cases of 
primary immunisation after an initial transfusion.  
Based on recent UK haemovigilance data from 
Serious Hazards of Transfusion (SHOT), a total of 
1681 cases were reported in 2014. Of these cases, 
there were 151 (8.9%) cases with RBC alloantibodies 
and 46 (2.7%) cases with HTRs from which 18 acute 
and 28 delayed hemolytic transfusion reactions [14]. 
HTRs and related mortality have been reported to 
occur at approximately 1 in 76,000, and 1 in 1.8 
million units transfused, respectively [15, 16]. The risk 
of death from a DHTR is approximately 1 fatality per 
3.85 million units (1 per 1.15 million units in patients 
who have received transfusions) [12]. 
Nowadays, we see RBC alloimmunization 
more as a problem of the laboratory to provide 
compatible blood for transfusion because this process 
is time-consuming and often causes a delay in 
transfusion treatment. The most frequent 
alloantibodies identified in transfused patients and 
different groups of chronically transfused patients 
(sickle cell disease, myelodysplastic syndrome or 
chronic myelomonocytic leukaemia as well as in 
nonhematologic patients) are within the Rh and Kell 
system [10, 11, 17, 18]. These findings suggest that it 
is vice to perform extended typing for chronically 
transfused patients at least for Rh (C, c, E, e) and Kell 
antigens before the initial RBC transfusion. For this 
purpose, it is also rational to have already typed RBC 
in the blood supply. 
 
Sickle cell disease patients are at particular 
risk of alloimmunization, which can be reduced by red 
cell phenotyping before the first transfusion followed 
by routine matching for at least the Rh and Kell 
groups [19]. This has been challenged by a recent 
study that showed no difference in alloimmunization 
rates between centres in the United States that 
provided closer antigen matching compared to those 
who did not [20]. 
However, most investigators agree that the 
extended RBC typing (beyond the routine ABO/D 
typing) has a beneficial effect on the incidence of 
alloimmunization in thalassemia major patients [18, 
21]. It has been shown that nonhematooncologic 
alloimmunized patients are high antibody responders, 
with a more than 20 times increased risk to form 
antibodies compared to first-time alloimmunization 
risk. If extended matching for C, c, E, K, Fy(a), and 
Jk(a) antigens in the future is considered, this group 
should be taken into account [22].  According to the 
data on the estimated frequency of clinically 
significant red blood cell antigens, there is no 
significant difference between the multiply transfused 
patients and the blood donors in the absence of race 
differences [11]. Individuals from ethnic minority 
groups have an increased risk of alloimmunization 
from transfusion because notable differences exist in 
the frequency of blood cell antigens between races. 
Efforts to increase the blood supply from minority 
donors are essential to reduce the frequency of 
alloimmunization in these groups [12]. 
However, total prevention of RBC 
alloimmunization and HTRs is unrealistic, because 
current immunohematological methods of testing are 
not sensitive enough to detect all RBC antigen and 
antibodies. In the early 2000s the EU BloodGen group 
was established with the aim of improving patient 
safety and blood transfusion compatibility through 
validation and standardisation of molecular 
genotyping approaches and to prove its superiority 
over currently applied serological testing [23]. 
BLOODchip is an integrated circuit that determines 
the main allelic variants of blood groups and platelet 
antigens by analysing 128 genetic polymorphisms. It 
is used to prevent potential transfusion reactions in 
those patients for whom conventional serologic tests 
are insufficient. It is still too early to determine whether 
proposals to minimise RBC alloimmunization through 
large-scale molecular RBC typing for all patients 
would be more efficient since the genotyping is no 
longer regarded as being more costly than serology 
[24]. Speaking of RBC alloimmunization, blood banks 
and immunohematology laboratories can not influence 
the demographic structure of the patients, neither the 
number of transfusions. What they can do is to 
choose and to optimise the method and the extent of 
RBC antigen typing and donor/recipient matching are 
providing more timely the most compatible blood for 
transfusion.
 
In conclusion, there was no significant 
difference according to the sex, diagnosis and number 
of transfusions, except for the incidence of 
alloimmunization between the group of transfused 
patients in the period before and the patients 
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transfused after the introduction of extended RBC 
typing. Although, the incidence of alloimmunization did 
not change (0.11% vs. 0.10%) over the time in the 
patients who were not multiply transfused it was not 
the case for the multiply transfused patients. The 
incidence of alloimmunization in the multiply 
transfused patients significantly decreased from 
33.9% to 17.5% which lead to the decrease of the 
overall incidence of RBC alloimmunization in 
transfused patients from 0.51% to 0.32% respectively.  
The current frequency of anti-E (25.6%) and -
K (12.8%) antibodies in transfused patients are 
significantly lower than their previous estimated 
frequencies of 30.4% and 24.0% respectively, as well 
as the overall frequency of RBC antibodies to Rh+Kell 
antigens which decreased from 72.4% to 53.8%. We 
believe that the extended donor-recipient matching for 
C, c, E, e and Kell antigens has a beneficial effect on 
the incidence of RBC alloimmunization especially for 
multi transfused patients. Currently, approximately 
30% of the available RBC units are typed for CEce/K 
within the corresponding ABO/D blood group. Our 
goal is to reach the number of 50% of Rh, and Kell 
typed RBC in our blood supply which would be 
sufficient to meet the needs for antigen negative RBC 
for most of the alloimmunized patients at any time. At 
this point and with the currently employed serologic 
methods there is no rational for routine donor/patient 
typing beyond ABO, Rh, and Kell systems in our 
transfusion practice.
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